Across TCGA pan-cancer cohorts, C1QTNF4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C1QTNF4 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C1QTNF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C1QTNF4 expression acts as an unfavorable survival marker.
LIHC and KIRC are the cancer types where C1QTNF4 Mutation most reproducibly stratifies survival.